

Response to reviewer #1:

1. Abbreviation of SVR and GFR elaborated.
2. On page 7, CC and TT are subtypes of IL28B genotype mentioned
3. On page 7, Sofosbuvir is a NS5B inhibitor mentioned.
4. On page 10, Ombitasvir is a NS5A inhibitor mentioned.
5. On page 13, Elbasvir is a NS5A inhibitor mentioned.
6. References have been given on page 10, 12, 15, 17-19, 21, 22
7. All drug drug interactions have been referenced.
8. Posology have been referenced.
9. List of drugs on page 36 have been placed in a table.
10. Indications of treatment described between pages 38 to 50 have been placed in tables.
11. In the section of HCV/HIV co-infection, sources of information have be mentioned.
12. In post-liver transplant patients, data have been placed in 2 tables as in one it was difficult to accommodate all data, and sources have been mentioned.
13. More data have been given on resistance-associated substitutions in DAA failure section.
14. Several writing errors in the entire manuscript have been corrected – green highlighted.

Response to reviewer #2:

1. references of drug drug interactions have been mentioned.
2. Sources of treatment protocols have been given.
3. The sources of information about treatment have been mentioned in the individualized treatment option section.